Research Spotlight – December 2018

Our December edition of Research Spotlight features 10 recent research discoveries from scientists whom Boster has served.

This month’s selected research publications cover disease areas from arthritis to diabetes to Parkinson’s and include studies that examine NK cells and PD-L1 expressions.

Scroll down to learn more about these new scientific discoveries.

Troubleshooting Guides

Download troubleshooting handbooks for IHC, Western blot and ELISA for FREE.

troubleshooting_box_image Troubleshooting guides
SIRT1 activation promotes angiogenesis in diabetic wounds by protecting endothelial cells against oxidative stress
Authors: Li, X., Wu, G., Han, F., Wang, K., Bai, X., Jia, Y., Li, Z., Cai, W...
Journal: Archives of Biochemistry and Biophysics
Objective: Chronic wounds are a devastating complication of diabetes and can lead to amputations or even death. Current medical therapies are insufficient to accelerate its repair. The objective of this study was to explore the role of Sirtuin1 (SIRT1) in…

Read More
Journal Cover
Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome
Authors: Peng, X., Yang, T., Liu, G. Liu, H., Peng, Y., & He, L.
Journal: International Immunopharmacology
Background: Lupus nephritis (LN) is a leading cause of mortality. The activation of NLRP3 inflammasome contributed to LN development and thus became a therapeutic target. Here we assessed the therapeutic potential of piperine, a bioactive…

Read More
Journal Cover
Effect of miR-30e regulating NK cell activities on immune tolerance of maternal-fetal interface by targeting PRF1
Authors: Huang, Q., Ding, J., Gong, M., Wei, M., Zhao, Q., & Yang, J.
Journal: Biomedicine & Pharmacotherapy
Aim: Natural killer (NK) cells, as key regulatory cells, accumulate at the maternal-fetal interface in large numbers. This study explored the effect of miR-30e on regulating the activity and function of peripheral blood NK cells (PB-NK cells) and decidua NK cells…

Read More
Journal Cover
Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection
Authors: Zhou, J., Liu, Z., Chen, M., Luo, Z.H., Li, Y.Q., Qi, G.Y., & Liu, T.
Journal: Diabetes Therapy
Introduction: Conbercept is a new anti-vascular endothelial growth factor drug approved for the treatment of age-related macular degeneration by the China Food and Drug Administration (CFDA) in 2013. In this study, we for the first time evaluated the...

Read More
Journal Cover
Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
Authors: Marques, T.M., van Rumund, A., Bruinsma, I.B., Wessels, H.J.C.T...
Journal: Molecular Neurobiology
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in elderly people. Currently, the diagnosis of PD is based on neurological examination, neuroimaging, and the response to dopaminergic medication. The diagnosis...

Read More
Journal Cover
Cinnamaldehyde ameliorates STZ-induced rat diabetes through modulation of IRS1/PI3K/AKT2 pathway and AGEs/RAGE interaction
Authors: Abdelmageed, M.E., Shehatou, G.S., Abdelsalam, R.A., Suddek...
Journal: Naunyn-Schmiedeberg's Archives of Pharmacology
Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder considered to be the most predominant form of diabetes throughout the world. This study aimed to investigate the possible effects of cinnamaldehyde (CIN) on insulin signaling pathways in STZ-induced…

Read More
Journal Cover
Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy
Authors: Guan, X., Lin, L., Chen, J., Hu, Y., Sun, P., Tian, H., Maruyama, A...
Journal: Journal of Controlled Release
The immune checkpoint blockade of programmed death ligand-1 (PD-L1) or programmed death-1 (PD-1) has been a promising strategy to restore T cell mediated tumor suppression. In this study, a plasmid DNA which expressed small hairpin RNA...

Read More
Journal Cover
Autocrine VEGF signalling on M2 macrophages regulates PD‐L1 expression for immunomodulation of T cells
Authors: Lai, Y.S., Wahyuningtyas, R., Aui, S.P., & Chang, K.T.
Journal: Journal of Cellular and Molecular Medicine
M2‐polarized macrophages, on one hand, can promote tumour vascularization by producing proangiogenic factors, such as vascular endothelial growth factor (VEGF). On the other hand, the expression of VEGF receptors (VEGFR) in this cell lineage was also…

Read More
Journal Cover
The involvement of C5a in the progression of experimental arthritis with Porphyromonas gingivalis infection in SKG mice
Authors: Munenaga, S., Ouhara, K., Hamamoto, Y., Kajiya, M., Takeda, K...
Journal: Arthritis Research & Therapy
Background: Epidemiological evidence to suggest that periodontal disease (PD) is involved in the progression of rheumatoid arthritis (RA) is increasing. The complement system plays a critical role in immune responses. C5a has been implicated in…

Read More
Journal Cover
GDF11 antagonizes TNF-α–induced inflammation and protects against the development of inflammatory arthritis in mice
Authors: Li, W., Wang, W., Liu, L., Qu, R., Chen, X., Qiu, C., Li, J., Hayball, J...
Journal: The FASEB Journal
Growth differentiation factor 11 (GDF11), a key member of the TGF-β superfamily, plays critical roles in various medical conditions. Recently, GDF11 was found to suppress the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway...

Read More
Journal Cover

Why Boster?

Get better results with Boster!

Boster takes great measures to ensure product quality and to provide our customers with comprehensive data upfront. Our antibodies are validated using WB, IHC, and flow cytometry against a panel of over 250 tissues and un-transfected cell lines to ensure high affinity and crystal-clear IHC stains. In addition, we also validate our antibodies in a quantitative fashion by testing them on known quantities of recombinant proteins so that you know what to expect (e.g. if there is 1ng, 2.5ng or 5ng of the target protein in the sample). Every product is covered by the Boster Quality Guarantee, click below to learn more.

Learn More

Supporting Our Customers

Have questions? We're here to help.